icer white paper affordable access to glp-1 obesity medications 2025 glp #obesity ICER releases obesity medicines white
Description
Theyre typically prescribed for obesity or type 2 diabetes, with potential side effects
Three large observational studies provide more data
Take our free, confidential eligibility assessment.
PlexusDx offers prescription-strength GLP-1 therapy tailored to your genetic profile
Beyond these, in the pre-clinical space, over 25 candidates have been disclosed, but our analysis of patents, company disclosures, and early-stage publications identifies nearly 70 additional undeclared pre-clinical programs
Stay on track with personalised goals, protein targets & healthy habits.
